Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, KLEMP WALTER V, holds the title of CEO and President at Moleculin Biotech, Inc..
On 2026-11-16, the insider transacted 718 shares.The shares were transacted at a weighted average price of $1.46 per share, resulting in a total market-relevant value of $1K.
KLEMP WALTER V (CEO and President) had withheld for taxes $1K of $MBRX
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.